ifosfamide has been researched along with Genital Neoplasms, Female in 23 studies
Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 9.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 9.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 7.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 7.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 5.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
| " Even at the lowest dose level tested (paclitaxel 135 mg/m(2) followed by ifosfamide 1 g/m(2)/day x 4 days) grade 4 neutropenia was almost universal, despite the routine use of G-CSF." | 5.09 | Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study. ( Burger, RA; Carson, LF; Gallion, H; Lentz, SS; Markman, M; Spriggs, D, 2001) |
| "Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship." | 5.08 | Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 3.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 3.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "Twenty-two patients with brain metastases at initial diagnosis were identified within a cohort of two hundred thirty-one consecutive patients with advanced metastatic disease, entered on a German multicenter trial between January 1993 and July 1998." | 2.69 | First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ( Bamberg, M; Beyer, J; Böhlke, I; Bokemeyer, C; Derigs, G; Hartmann, JT; Kanz, L; Kollmannsberger, C; Nichols, C; Rüther, U; Schleucher, N; Schmoll, HJ; Schöfski, P, 2000) |
| "Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 2.67 | Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
| " Based on these findings, the author established a consecutive low-dose CDDP dosing method, which possibly could deliver a higher therapeutic index compared with the bolus-dosing method." | 2.40 | [Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. ( Shimizu, Y, 1997) |
| "In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses." | 2.38 | Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992) |
| "Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class." | 1.28 | Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991) |
| "Ifosfamide is an active chemotherapeutic agent in a wide range of gynecologic tumors; favorable response rates have been reported in ovarian (epithelial and germ cell), uterine, and cervical neoplasms." | 1.28 | Ifosfamide-induced neurotoxicity. ( Curtin, JP; Gutierrez, M; Koonings, PP; Morrow, CP; Schlaerth, JB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 17 (73.91) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Rijswijk, RE | 1 |
| Vermorken, JB | 1 |
| Reed, N | 1 |
| Favalli, G | 1 |
| Mendiola, C | 1 |
| Zanaboni, F | 1 |
| Mangili, G | 1 |
| Vergote, I | 1 |
| Guastalla, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| Lacave, AJ | 1 |
| Bonnefoi, H | 1 |
| Tumulo, S | 1 |
| Rietbroek, R | 1 |
| Teodorovic, I | 1 |
| Coens, C | 1 |
| Pecorelli, S | 1 |
| Leyvraz, S | 2 |
| Zweifel, M | 1 |
| Jundt, G | 1 |
| Lissoni, A | 2 |
| Cerny, T | 2 |
| Sessa, C | 2 |
| Fey, M | 1 |
| Dietrich, D | 1 |
| Honegger, HP | 1 |
| Saito, G | 1 |
| Yoshimura, S | 1 |
| Iwasaki, K | 1 |
| Kuroshima, Y | 1 |
| Moriuchi, T | 1 |
| Bhardwaj, A | 1 |
| Badesha, PS | 1 |
| Behbakht, K | 1 |
| Massad, LS | 1 |
| Yordan, EL | 1 |
| Lincoln, SH | 1 |
| Eriksson, JA | 1 |
| Winkelman, L | 1 |
| DeGeest, K | 1 |
| Kirschner, C | 1 |
| Wilbanks, GD | 1 |
| Manegold, C | 1 |
| Shimizu, Y | 1 |
| du Bois, A | 1 |
| Vach, W | 1 |
| Siebert, C | 1 |
| Holy, R | 1 |
| Ledergerber, M | 1 |
| Wechsel, U | 1 |
| Kriesinger-Schroeder, H | 1 |
| Bacchi, M | 1 |
| Bressoud, A | 1 |
| Hermann, R | 1 |
| Kollmannsberger, C | 1 |
| Nichols, C | 1 |
| Bamberg, M | 1 |
| Hartmann, JT | 1 |
| Schleucher, N | 1 |
| Beyer, J | 1 |
| Schöfski, P | 1 |
| Derigs, G | 1 |
| Rüther, U | 1 |
| Böhlke, I | 1 |
| Schmoll, HJ | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Lopez, AM | 1 |
| Ketchum, M | 1 |
| Nichols, H | 1 |
| Xu, MJ | 1 |
| Peng, YM | 1 |
| Dorr, R | 1 |
| Alberts, DS | 1 |
| Markman, M | 1 |
| Spriggs, D | 1 |
| Burger, RA | 1 |
| Carson, LF | 1 |
| Lentz, SS | 1 |
| Gallion, H | 1 |
| Thigpen, T | 2 |
| Lambuth, BW | 2 |
| Vance, RB | 2 |
| Sutton, GP | 2 |
| Blessing, JA | 2 |
| Manetta, A | 1 |
| Homesley, H | 1 |
| McGuire, W | 1 |
| Weiss, RB | 1 |
| Nishida, T | 3 |
| Nagasue, N | 3 |
| Izumi, S | 1 |
| Sakihama, H | 1 |
| Yakushiji, M | 2 |
| Curtin, JP | 1 |
| Koonings, PP | 1 |
| Gutierrez, M | 1 |
| Schlaerth, JB | 1 |
| Morrow, CP | 1 |
| Photopulos, G | 1 |
| Berman, ML | 1 |
| Homesley, HD | 1 |
| Berger, DP | 1 |
| Fiebig, HH | 1 |
| Winterhalter, BR | 1 |
| Wallbrecher, E | 1 |
| Henss, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma[NCT00002526] | Phase 2 | 20 participants (Actual) | Interventional | 1993-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ifosfamide and Genital Neoplasms, Female
| Article | Year |
|---|---|
[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1997 |
The role of ifosfamide in gynecologic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Genital Neoplasms, Female; Humans | 1992 |
Gynecologic Oncology Group studies with ifosfamide.
Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita | 1992 |
Ifosfamide in the management of gynecologic cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Humans; Ifosfamid | 1990 |
7 trials available for ifosfamide and Genital Neoplasms, Female
| Article | Year |
|---|---|
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Doxorubicin; | 2003 |
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Femal | 2006 |
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon | 1998 |
First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality | 2000 |
A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2000 |
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2001 |
Gynecologic Oncology Group experience with ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
12 other studies available for ifosfamide and Genital Neoplasms, Female
| Article | Year |
|---|---|
Suppression of plasma glutathione peroxidase activity by ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Glutathione Perox | 1994 |
Ifosfamide-induced nonconvulsive status epilepticus.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; | 1995 |
A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Combined Modali | 1996 |
[Ifosfamide].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 1996 |
The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp | 1997 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug | 1990 |
Ifosfamide-induced neurotoxicity.
Topics: Adult; Aged; Central Nervous System; Creatinine; Drug Administration Schedule; Female; Genital Neopl | 1991 |
Ifosfamide in gynecological tumors. Satellite symposium of 5th European Conference on Clinical Oncology and Cancer Nursing. London, September 3-7, 1989. Proceedings.
Topics: Female; Genital Neoplasms, Female; Humans; Ifosfamide | 1990 |
Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Genital | 1990 |
Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Topics: Animals; Cyclophosphamide; Drug Evaluation, Preclinical; Drug Resistance; Female; Genital Neoplasms, | 1990 |
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1988 |